All posts by medical

Neuroscience

Sparticipation goes virtual: Organizations face technical difficulties, low turnout – The State News

This years Sparticipation will go down in the history books as one of the most unique ever conducted.

Because of the ongoing COVID-19 pandemic, Sparticipation 2020 was held virtually. This year, the annual kickoff event of welcome week that hosts clubs, organizations, businesses and more was held over the course of three days Monday to Wednesday from 5 to 8 p.m.

In the online format, participants entered in the virtual fair and were allowed to visit any desk and message any club of their choosing. From there, participants could ask questions via a chat room.

Despite the lack of a real human connection, Chief Executive Officer of the Hospitality Association Brendan Connolly was happy the university found a way to proceed with the event.

This is certainly a new and unusual set-up for Sparticipation, but I am happy to see the event take place in a safe way, Connolly said. I have to hand it to the group that puts together Sparticipation each year, they were very dynamic and pivoted to a platform that was appropriate for the current climate.

Impressed by the transition to an online platform, Connolly was happy to see the event go on, even if it wasn't the same as previous years.

"It would have been all too easy for them to cancel the event this year," he said. "Instead, they actively prioritized the student experience and created an opportunity for students to engage in extra-curricular (activities) that prioritizes everyones safety."

The Associated Students of Michigan State University, or ASMSU, typically draws foot traffic during a normal Sparticipation. While the online system can make for awkward situations, ASMSU Vice President for Internal Administration Nora Teagan said the virtual event may allow them to reach more students than ever before.

So far it is pretty interesting, Teagan said. As someone 'running' a booth we had training sessions to understand how to run this online system. It is kinda difficult to connect with students on this platform but the chat function makes it better! I think with having this over three days will allow students to connect with more clubs than before.

The MSU neuroscience club had success with this new program but also utilized Zoom for a more personalized experience.

"The conversations I have had have been great," MSU Neuroscience Outreach Chair Hailey Bond said. "I have been able to set up communication with many people at once and effectively answer questions in ways that they are comfortable. I spent about five minutes connecting with an incoming freshman via zoom. I could tell our conversation made her more at ease and cleared up some confusion."

However, many clubs saw a drop in visits by students in the new platform on Day One, including Arc, a club that connects LGBTQIA+ students to others on MSUs campus.

Digital and social are not really friends for such a large event like this, a member of Arc that asked to remain anonymous said. Sparticipation is usually where clubs receive their largest influx of members, and I just havent connected with anyone online here. Only maybe 3 people! Thats a really awful stat considering we usually get interest around 100+!

They also said that the lack of advertising could be a factor in the smaller amount of participants. In a typical year, MSU would close dining halls to encourage attendance. This year, students did not even receive an email from the university about the event.

Most kids Ive talked with have never heard of the event when I told them it was coming, the member said.

The turnout for the ASMSU desk was steady according to Teagan, but certainly not as much as a normal year.

Turnout so far has been steady, Teagan said. We have had a lot of students visiting our page and a few on there engaging in the chat feature. Definitely not as many as we would have at an in person Sparticipation, but it is just the beginning of this event.

The chat feature could be utilized in a private or public setting. Participants could directly message hosts of the desk from the homepage, or the hosts could directly message while participants were in their booth area or while on the homepage. Some had trouble working the chat feature despite being able to receive some of the same questions they would normally get at the event.

Usual questions wed get at a regular Sparticipation, though there seems to be a lot of confusion with the chat function, the Arc member said. Some people didnt know they were talking to me, they thought I was from another club or they didnt understand the messaging system or it disappeared all together!

Some of the issues found by participants were disappointing, especially as students try to find the connections they desire while at home.

Im not sure if its the site being glitchy, the fact it wasnt advertised, that people find it hard to join digital events, or if people just arent visiting booths they normally would, but its difficult to navigate and clubs are more important than ever when kids are stuck at home and need to feel engaged, the Arc member said.

Arc was not the only club who had setbacks with the website either as Spartans Involved in Community Service thought the program was clunky at times.

"The site seems a little clunky," Vice President of Spartans Involved in Community Service Duncan Begley said. "Especially the chat system. You have to close the chat to do anything else and when you're talking to multiple people it can get pretty slow navigating the tiny menu."

Despite the setbacks with the site, clubs are looking to try and make the experience as enjoyable as possible.

We want to help them find the right group for them, Connolly said. Maybe a friend of mine is in a club that aligns with this particular student's passions or I saw another booth that might interest them. At the end of the day, we are all just Spartans trying to help Spartans out.

Discussion

Share and discuss Sparticipation goes virtual: Organizations face technical difficulties, low turnout on social media.

Read the original post:
Sparticipation goes virtual: Organizations face technical difficulties, low turnout - The State News

Cell Biology

University subject profile: biosciences – The Guardian

What youll learnThe biosciences are a wide field including human biology, bioinformatics, botany, zoology, genetics, microbiology and biochemistry. What youll learn depends on how you decide to specialise you could learn the fundamentals of cell biology, the computer skills needed to understand protein sequences, or the mating habits of an orangutan.

Youll know how to research information, how to apply it and how to use specialist equipment. And youll develop an understanding of the ethical considerations associated with your field of study.

How youll learnYoull spend a lot of your time in the laboratory doing practical work, and most courses require students to conduct their own research. There will probably be group projects, so youll learn how to work in a team. Chances are youll be taught by those at the cutting edge of research. Assessment will involve a mix of coursework, projects and exams.

Some courses offer a year in industry a good way of building your CV.

Entry requirementsUniversities are likely to expect biology at A-level or equivalent, and sometimes chemistry. They may also ask for an additional science or maths (or further maths or pure maths). Course requirements will likely range from CCC to AAA. You may be required to attend an interview and give a short presentation on a topic in your field of study.

What job can you get?Lots of jobs are suited to biosciences graduates, but if you want to work as a scientist youll need to do further study at postgraduate level. If you want to specialise, your degree should give you the skills to turn your hand to forensic science, immunology and toxicology, to name but a few. You could then find suitable research posts in the public and private sector particularly in industry or in academia. According to Ucas, many biosciences graduates end up in the health and social care sector, and in education.

But the skills you acquire will also qualify you for jobs outside the lab. Work can be found in local and central government, in NGOs, doing conservation work, and in teaching.

More:
University subject profile: biosciences - The Guardian

Cell Biology

Russian coronavirus vaccine results have been published heres what they reveal – Australian Times

Anne Moore, University College Cork

President Vladimir Putin recently announced that a team of Russian scientists had developed a COVID-19 vaccine and that it had been approved for use by the regulators at least, in Russia.

However, the announcement caused consternation among scientists and clinicians in the rest of the world as human trials for the vaccine nicknamed Sputnik V had only started a couple of months before Putins announcement.

The results of the phase one and two human trials of this vaccine have just been published in The Lancet. So what have we learned?

First, lets look at what type of vaccine this is. The vaccine platform used in this study used adenoviruses. These common cold viruses, called Ad5 and Ad26, are made safe and are incapable of growing in the body. They only function to deliver the genetic code of one of the novel coronavirus proteins, called the spike protein, into a cell.

By injecting people with these modified adenoviruses, the immune system is stimulated to respond to the spike protein at the time of immunisation, and hopefully to respond for many years in the future, if the immunised person is exposed to the COVID-causing coronavirus, known as SARS-CoV-2.

The vaccine platform the Russians are using is not novel. Some of the leading COVID-19 vaccines use adenoviruses, including the Oxford University vaccine and an Ad26 vaccine developed by Johnson and Johnson. Following successful animal trials, both are now being tested in humans. CanSino Biologicals, a Chinese company, has also shown that its Ad5 vaccine is safe and induces immunity against the coronavirus in humans.

However, the Russian group has shown that their stable, freeze-dried preparation of the vaccine works to the same extent as their frozen liquid vaccine preparation. This is important for shipping and deploying a vaccine.

The Lancet paper outlines acceptable safety data, even with the high dose used. These safety results are not unexpected as the safety of several adenovirus-based vaccines for different diseases has been demonstrated in earlier research.

So its safe, at least in healthy people aged 18 to 60, but does it work does it protect against COVID-19?

The Russian group showed that their vaccine induces high levels of antibodies that can bind to the spike protein. But a more important measure is the level of antibodies that are functional. That is, can the antibodies prevent, or neutralise, infection of a virus into a cell?

The levels of neutralising antibodies were quite low in this study, compared with other published vaccine trials. So too were the T cell responses (the other arm of the immune systems adaptive response).

One interpretation of this is that these vaccines do not induce good neutralising protection. Alternatively, the methods used to measure these immune responses may not have been optimal. In the absence of international reference standards, we cant tell if this vaccine is better or worse compared with others.

Crucially, as with other COVID-19 vaccine clinical trials, we dont know if that level of neutralisation is enough to protect from infection and how long these antibodies remain in the blood. The publication shows responses only up to one month after immunisation. The ultimate question of whether these vaccinated people are protected against COVID-19 was not a focus of this paper.

Despite the positive results of the small phase one trial of the Sputnik V vaccine, it needs to be tested in a much larger group of people before it can be used on an entire population with confidence.

All vaccines need to be tested in large numbers of people, of different ages and ethnicities, in phase three clinical trials. Phase three trials are necessary to gain a high level of confidence that the vaccine protects against infection. They also help to tease out rare side effects that may not be evident in a small group of healthy volunteers. This final stage of testing is not one that can or should be left out.

Unfortunately, the Sputnik moniker highlights the politicisation of earnest scientific and medical efforts to develop vaccines against COVID-19. This vaccine nationalism is a source of much concern for everyone in the vaccine field who understands the power of vaccines to eliminate disease, but only when used with the acceptance of the population.

Anne Moore, Senior Lecturer in Biochemistry and Cell Biology, University College Cork

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Visit link:
Russian coronavirus vaccine results have been published heres what they reveal - Australian Times

Cell Biology

Single-Cell Omics Market Top Participant To Focus On Regional Expansion the COVID-19 – Scientect

The global single-cell omics market is expected to grow from $555.3 million in 2017 to nearly $1.6 billion in 2022, at a compound annual growth rate (CAGR) of 23.5% from 2017 to 2022.

Report Scope:

The scope of this report includes single cell analysis technologies, applications, industries, major funding initiatives, patents and companies. The market sizes for single cell products are given for the years 2015, 2016, 2017 (estimated) and 2022 (forecasted).

This report reviews the single cell workflow steps and technologies and provides background on why single cell analysis is important. It then discusses some of the top research initiatives that are contributing to single cell applications. Market driving forces are also discussed.

Request For Report sample @ https://www.trendsmarketresearch.com/report/sample/12204

The structure of several important industry subsectors is reviewed, as well as major industry acquisitions and strategic alliances from Jan. 2016 to Sept. 2017. Industry subsectors analyzed include target enrichment, droplet digital PCR, single cell DNA polymerase, DNA amplification, next generation sequencing (NGS) instruments, single cell proteomics, circulating tumor cell (CTC) capture and detection, liquid biopsy, preimplantation testing and immune sequencing.

The market for single cell analysis technologies is analyzed in depth. The market is analyzed by end user, application field, product type, omics method used, cell type, clinical indication and geography.

Specific geographic markets are discussed, including North America, Europe, Asia-Pacific and the rest of the world.

Market data covers the years 2015, 2016, 2017 (estimated) and 2022 (forecast).

More than 90 companies in the single cell analysis industry are profiled in this report.

BCC Research provides a summary of the main industry acquisitions and strategic alliances from Jan. 2016 through Sept. 2017, including key alliance trends.

Report Includes:

71 tables An overview of the global markets and emerging technologies for single-cell genomics and proteomics Analyses of global market trends, with data from 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022 Cell isolation technologies, including flow cytometry, laser capture microscopy, and micromanipulation Sample preparation technologies, including microfluidics, whole genome amplification/pre-amplification Analyses of next-generation sequencing, qPCR/PCR, microarrays, mass spectrometry, and microfluidics End-use industry coverage, including research, drug discovery and development, diagnostics, and applied Evaluation of the markets dynamics, including growth drivers, restraints, and opportunities Profiles of major players in the industry including 1 Cellbio, 10x Genomics Inc., Angle PLC, Aviva Biosciences, Boreal Genomics, Dolomite Bio and Hifibio

Summary

Single-cell omics analysis technologies are emerging as a disruptive force in the life science research, pharmaceutical and diagnostics industries. Single cell analysis is critical for analyzing complex, heterogeneous biological systems that occur at many levels of life sciences from stem cell biology to cancer to forensics.

In cancer, for example, a tumor may shed cells into the bloodstream that give clues about the aggressiveness of that tumor or how it is responding to a particular drug therapy. It is important to analyze these individual cells, called circulating tumor cells, to aid in monitoring the disease or to guide therapy strategies. The emerging field of liquid biopsy addresses this medical need.

Single-cell omics are also important to fundamental biological research, for example, to identify cancer mutation drivers or factors that influence stem cell potency. The trend toward biological drugs, stem cell therapies and new cancer treatments is also beneficial to the single cell analysis markets due to its importance in these fields.

Report Scope:

The scope of this report includes single cell analysis technologies, applications, industries, major funding initiatives, patents and companies. The market sizes for single cell products are given for the years 2015, 2016, 2017 (estimated) and 2022 (forecasted).

This report reviews the single cell workflow steps and technologies and provides background on why single cell analysis is important. It then discusses some of the top research initiatives that are contributing to single cell applications. Market driving forces are also discussed.

The structure of several important industry subsectors is reviewed, as well as major industry acquisitions and strategic alliances from Jan. 2016 to Sept. 2017. Industry subsectors analyzed include target enrichment, droplet digital PCR, single cell DNA polymerase, DNA amplification, next generation sequencing (NGS) instruments, single cell proteomics, circulating tumor cell (CTC) capture and detection, liquid biopsy, preimplantation testing and immune sequencing.

The market for single cell analysis technologies is analyzed in depth. The market is analyzed by end user, application field, product type, omics method used, cell type, clinical indication and geography.

Specific geographic markets are discussed, including North America, Europe, Asia-Pacific and the rest of the world.

Market data covers the years 2015, 2016, 2017 (estimated) and 2022 (forecast).

More than 90 companies in the single cell analysis industry are profiled in this report.

BCC Research provides a summary of the main industry acquisitions and strategic alliances from Jan. 2016 through Sept. 2017, including key alliance trends.

Reasons for Doing This Study:

The life science industry is moving towards digitization with the advent of newer technologies including advanced genetic sequencing and microfluidics systems. As many biological systems contain heterogeneous populations of cells, heretofore many analysis methods measured mixtures of different cell types.

Single cell analysis is a disruptive technology that enables analysis of single cells out of a complex mixture of cells. This type of analysis is key to understanding complex systems in fields as diverse as neurology, stem cell biology and cancer.

At the same time, advances in genome editing, high-throughput systems and microfluidics technologies have enabled the rapid, parallel analysis of smaller samples that are common with single cells. Based on this, single cell analysis markets are rapidly emerging and the need for industry and market characterization is great.

Also, the single cell field is growing beyond basic research into applied fields and molecular diagnostics applications.

The outstanding growth potential for single cell analysis products makes it particularly timely for doing this updated report.

More Info of Impact Covid19 @ https://www.trendsmarketresearch.com/report/covid-19-analysis/12204

See original here:
Single-Cell Omics Market Top Participant To Focus On Regional Expansion the COVID-19 - Scientect

Immunology

Worldwide Human Microbiome Immunology Therapeutics Industry to 2025 – The US Dominates the Global Market Landscape – PRNewswire

DUBLIN, Sept. 3, 2020 /PRNewswire/ -- The "Global Human Microbiome Immunology Therapeutics Market & Clinical Trial Insight 2025" clinical trials has been added to ResearchAndMarkets.com's offering.

The scale and scope of microbiome research activity has now become one of the fastest growing areas in biology. The relevance that it has shown for the welfare of the society and pharmaceutical industry has led to the development of a transdisciplinary environment that is however conducive to innovation with a mission to abolish the limitations in the pharmaceutical industry through excellence in microbiome research, awareness and outreach. Over the years now, gut microbiome is estimated to implicate success for the various immunotherapies.

Microbiome's role in immunology practices is to transform world-class treatment into the medicine of today and tomorrow. It is highly recognizable that the healthcare issues that mankind is facing today is now bigger than any one solution. The treatment of certain diseases requires multiple options for the treatment and ultimately prevention. Therefore, the amalgamation of two different treatment paradigms i.e. microbiome and immunology are apparently delivering some medical benefits that millions of patients were in need for long period of time. The ways in which microbiome is understood and manipulated to serve the immunological aspects has given great interest to all the researchers.

The essential and usual concept of immunology depicts targeting the immune system of the body to provoke an immune response with huge impact but then the unsuccessful implication of immunology therapies driven treatments led to an exploration of several other basic concepts that could play an important role in boosting the immune system when combined. Looking forward, the microbiome community in the gut represented beneficial patterns with respect to further research. The area of microbiome research and its combination with immunological aspect for the disease treatment has produced a real excitement in the area of medical research and specifically microbiome research.

All over the world, the amalgamation of the two has been well accepted and appreciated by the patients, physicians and the clinicians. Investigation of all the working sides of microbiome and how it plays an important role in boosting the manipulated immune cells have recently started in large numbers as the technology available in the medical field allows to capture it accurately. To facilitate the microbiome and immunology community in order to extract the best and trending opportunities that are stemmed into the microbiome research, the experts from both the relevant disciplines are analyzing it through clinical researches and surveys. Further, the area is getting supported by 86 different clinical trials getting conducted in different countries.

The Global Human Microbiome Immunology Therapeutics Market & Clinical Trial Insight 2025 report summarizes the view of the wider opportunities that are associated microbiome community for the advancement of the scientific information regarding immunology. The science that is related to microbiome has high interdisciplinary and various opportunities that somehow have remained hidden in the medical world. It is believed that the opportunities and all the desirable tangible benefits microbiome is capable of delivering when combined with immunology is large and needs coordinated and constructive approach. The call to the two different sectors i.e. microbiology and immunology is estimated to unlock the potential and promising benefits of microbiome. The approach leading to the extraction of advantages if properly embedded in the microbiome and immunology research, the future benefits will be huge

Report Highlights:

Key Topics Covered:

1. Overview of Microbiome1.1 Introduction to Microbiome1.2 History & Evolution of Microbiome

2. Role of Microbiome in Human Body

3. Microbiome: Various Forms3.1 Gut Microbiome3.2 Lung Microbiome3.3 Skin Microbiome3.4 Microbiome in Other Parts of the Body

4. Mechanism of Microbiome Activity4.1 Nature of Immune Response4.1.1 Immunosuppressive Activity4.1.2 Immunostimulatory Activity4.2 Messengers Involves in Microbiome Mechanism4.2.1 MAMPs/PAMPs4.2.2 Microbial Metabolites As Messengers4.2.3 Host Cytokines As Messengers4.2.4 Immune Cells As Messengers

5. Technological Requirement for Microbiota5.1 Technologies Used5.1.1 iChip5.1.2 Simulator of the Human Intestinal Microbial Ecosystem (SHIME)5.1.3 Gut-on-a-Chip System5.1.4 Colonic Stem Cell Construction5.2 Harnessing & Engineering the Microbiome5.2.1 Additive Approaches5.2.2 Subtractive Approaches

6. Need for Microbiome Immunology

7. Therapeutic Applications of Microbiome Immunology7.1 Microbiome Therapy7.2 Precision Medicine7.3 Drug discovery7.4 Biomarkers & Therapy Optimization

8. Human Microbiota in Infectious Diseases8.1 Infection with Clostridium Difficile8.2 Infection with Helicobacter Pylori8.3 Bacterial Vaginosis8.4 Infection with HIV

9. The Human Microbiota & Liver Diseases9.1 Non-Alcoholic Fatty Liver Disease (NAFLD)9.2 Alcoholic Liver Diseases (ALD)9.3 Liver Fibrosis & Cirrhosis

10. The Human Microbiota & Metabolic Disorders10.1 Obesity10.2 Type 2 Diabetes

11. The Human Microbiota & Other Diseases11.1 Microbiota & Allergic Diseases11.2 Microbiota & Psychiatric Diseases

12. Microbiome in Immuno Oncology12.1 Role of Microbiome in Immuno Oncology12.2 Microbiome Mechanism in Oncogenesis & Tumor Suppression

13. Microbiome Application by Cancer Types13.1 Gastric Cancer13.2 Colorectal Cancer13.3 Esophageal Cancer13.4 Hepatocellular Carcinoma13.5 Melanoma13.6 Solid Tumors

14. Industrial Approaches of Microbiome Therapy in Oncology14.1 Bacterial Approaches14.1.1 Fecal Microbiota Transplantation (FMT)14.1.2 Synthetic Bacteria14.1.3 Microbial Culture14.2 Microbiome as Vaccine14.3 Microbiome as Small Molecules14.4 Microbiome Therapy using Phage Virus

15. Global Human Microbiome Market Analysis15.1 Overview15.2 Human Microbiome Market Segmentation15.2.1 Regional Segmentation15.2.2 Disease Based Segmentation15.2.3 Segmentation by Application

16. Clinical Pipeline of Microbiome Based Therapy16.1 Microbiome Modulators in Clinical Trial16.2 Cancer Related Clinical Trials16.2.1 Preclinical & Discovery Phase16.2.2 Active Clinical Trials16.3 Clinical Trial Related To FMT16.3.1 Clinical Trial for Recurrent C. difficile16.3.2 Clinical Trial for Inflammatory Bowel Disease (IBD)16.3.3 Other FMT Related Clinical Trials

17. Global Microbiome Modulators Clinical Pipeline By Company, Indication & Phase17.1 Research17.2 Preclinical17.3 Clinical17.4 Phase-I17.5 Phase-I/II17.6 Phase-II17.7 Phase-II/III17.8 Phase-III

18. Marketed Microbiome Modulators Clinical Insight18.1 Sodium Oligomannurarate - Shanghai Green Valley Pharmaceutical18.2 Miya-BM

19. Global Microbiome Immunology Therapeutics Market Growth Drivers

20. Microbiome Technology - Investments, Acquisitions & Collaborations by Leading Microbiome Companies

21. Blockades in the Microbiome Immunology Market21.1 Stable Engraftment21.2 Development of Clinically Relevant Sensors21.3 Robustness and Evolutionary Stability of Genetic Circuits21.4 Regulation, Safety and Biocontainment

22. Global Microbiome Immunology Market Future Panorama

23. Competitive Landscape23.1 4D Pharma23.2 AbbVie23.3 AstraZeneca plc23.4 Biocodex23.5 Bristol Mayer Squibb23.6 Corebiome/Diversigen23.7 Elogi Bioscience23.8 Enterome23.9 Ferring Pharmaceuticals23.10 Finch Therapeutics23.11 Maat Pharma23.12 Merck23.13 Microbiome Therapeutics23.14 Novartis23.15 OpenBiome23.16 Pfizer23.17 Rebiotix23.18 Second Genome23.19 Seres Therapeutics23.20 Symberix23.21 Takeda Pharmaceuticals23.22 Vedanta Bioscience

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/u5kzzz

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Go here to see the original:
Worldwide Human Microbiome Immunology Therapeutics Industry to 2025 - The US Dominates the Global Market Landscape - PRNewswire

Anatomy

Whats Most Difficult About Playing A Doctor On Grey’s …

One of the things that medical shows, especially, have really tried to do is have an emphasis on how things actually work in a hospital and in surgery when such details are shown on camera. The goal, of course, is to have the procedures, equipment used, potential complications and everything else on Grey's Anatomy be as realistic as possible, so that viewers can really get into the stories without wondering too much about the authenticity of what they've seen. And, as Chandra Wilson said, one of the things the actors have to worry about is making sure that they respect the real professions they're portraying.

The rest is here:
Whats Most Difficult About Playing A Doctor On Grey's ...

Anatomy

Grey’s Anatomy Is Losing A Star To Station 19, But Why …

While Grey's Anatomy and sister series Station 19 have been off the air for months and there is no news of when exactly they might be back on ABC with new episodes, there is some big news for both shows. Grey's is losing another star for the sake of the spinoff, and there are already questions about why exactly it is happening from a story perspective, and what it will entail. Stefania Spampinato, a.k.a. Dr. Carina DeLuca, is switching from a recurring actor on Grey's Anatomy to a series regular on Station 19.

View original post here:
Grey's Anatomy Is Losing A Star To Station 19, But Why ...

Anatomy

Ellen Pompeo Reveals Her New Favorite Grey’s Anatomy …

Pompeo also responded to a fan who asked if season 17 would be about COVID-19, confirming what showrunner Krista Vernoff has previously said about the stories for the new season.

"Yes the biggest medical crisis the world has ever seen?" Pompeo tweeted. "Yes we are meeting the moment and telling some stories."

Vernoff has said that while she initially did not want to address the pandemic, the writers on her staff convinced her it would be "irresponsible" not to.

"[Doctors]were saying things like, kids, their first year out of medical school, are seeing more death in the first year than many doctors see in a decade, and it just felt like we had to tell this story," she said on THR's TV's Top 5 podcast. "We have to tell this story, and so the conversation became, how do we tell this very painful, brutal story that has hit our medical community so intenselyand as they keep saying, permanently changed medicine? How do we do that and provide some escapism? How do we do that and create romance and comedy and joy and fun?"

At the very least, it looks like the romance is still in the cards.

Read more from the original source:
Ellen Pompeo Reveals Her New Favorite Grey's Anatomy ...

Anatomy

‘Grey’s Anatomy’ Season 17: Everything We Know So Far …

They were saying things like, kids, their first year out of medical school, are seeing more death in the first year than many doctors see in a decade, and it just felt like we had to tell this story, she continued. We have to tell this story, and so the conversation became, how do we tell this very painful, brutal story that has hit our medical community so intenselyand as they keep saying, permanently changed medicine? How do we do that and provide some escapism? How do we do that and create romance and comedy and joy and fun?

On September 4, Pompeo implied that covering COVID-19 was a no-brainer for the series after being asked about it by a fan. Yes, she replied. The biggest medical crisis the world has ever seen? Yes we are meeting the moment and telling some stories.

The new season begins one month and a half into pandemic. Actor Giacomo Gianniotti, who plays Dr. Andrew DeLuca, teased details of season 17's coronavirus storyline, telling Entertainment Tonight the series will start about a month and a half [into] full COVID,so it's going to take place a little beyond where we left off in the last season."

We might have some flashbacks, he continued. "We might have some things where we're referencing last season, just to havecontext leading up. But we are going to have a littleleap when we start this season in terms of time. We're not picking up right where we left off."

Sorry, there will be less kissing. Vernoff told THR its safe to say the kissing quotient will be down in season 17. Obviously, you cant have people making out, but theres been a lot of sex on Greys Anatomy that doesnt involve kissing, she said. There's a lot of sexy lifting of clothes, and pulling down of clothes, and taking off of things, and standing behind a person in a sexy way. Theres a lot of ways to skin a cat, so to speak.

A few actors are getting bumped up to series regulars. Richard Flood and Anthony Hill are officially Greys Anatomy series regulars, according to the Hollywood Reporter. Meanwhile, Stefania Spampinato, who plays DeLucas sister, Carina, will be transitioning to a series regular role on its firefighter spin-off, Station 19.

Richard Flood as Dr. Cormack Hayes with Ellen Pompeo as Meredith Grey

Flood plays Dr. Cormack Hayes, the widowed pediatric surgeon whose relationship with Meredith is giving us major enemies-to-lovers vibes, while Hill portrays Dr. Winston Ndugu, Maggies (Kelly McCreary) next love interest.

I am so excited to add Anthony Hill, Stefania Spampinato, and Richard Flood to the Station 19 and Greys Anatomy families, said Krista Vernoff, who serves as showrunner on both dramas. They are huge talents who made a big impact with our fans, with our casts, and with our writers, who are eager to write more for them.

This post will be updated as new information becomes available.

Originally posted here:
'Grey's Anatomy' Season 17: Everything We Know So Far ...

Anatomy

University subject profile: anatomy and physiology – The Guardian

What youll learnIf you want to get under the skin of the human body and delve into the functioning of everything from the skeletal structure to the nervous system, an anatomy or physiology degree might be for you. You could learn how cells develop, how limbs form in the right places, even how muscle groups are used in different sports. You may touch on hot topics such as cell cloning, genetic engineering or the impact of malaria or HIV on a human being.

Anatomy degrees will involve dissection of human and animal cadavers, while physiology involves the study of both the healthy body and the body as affected by disease research which can lead to the development of new medical treatments. Degree courses will impart an excellent knowledge of how the body works and can encompass a variety of disciplines including biology, genetics, immunology, embryology, neuroscience, pharmacology and disease processes.

How youll learnCourses are hands-on, so you could be doing anything from dissection classes to fieldwork or data analysis. As well as learning independently, youll probably need to complete group work, and a hefty original research project in the final year. Expect to spend lots of your time in lectures, seminars and laboratory practicals.

Entry requirementsMany universities will ask for at least two A-Levels (or equivalent) in biology, chemistry, physics or maths. Psychology may also be desirable.

What job can you get?Many graduates work as physiotherapists, or in fields such as cardiology, audiology, neurophysiology, or speech and language therapy.

Others undertake further study, sometimes in medicine or dentistry. If you love the academic side, a career in scientific research could be right up your street. This will require extra study, but you will be able to specialise in an area of particular interest. This doesnt always mean you need to stay in a university pharmaceutical companies, charities and government departments need researchers too.

Teaching is another option, while the analytical and data-handling skills youll gain should make you an attractive candidate for multinational corporations.

Originally posted here:
University subject profile: anatomy and physiology - The Guardian